Med Student Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Flibanserin demonstrates efficacy and tolerability in pivotal Phase III Trials in pre-menopausal women with Hypoactive Sexual Desire Disorder
Boehringer Ingelheim, 11/17/09

Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number of Satisfying Sexual Events and sexual desire while significantly decreasing the distress associated with Hypoactive Sexual Desire Disorder.1 Flibanserin is an investigational compound that is being developed by Boehringer Ingelheim for the treatment of pre–menopausal women with HSDD.